Every 10-Q that Dianthus Therapeutics, Inc. (DNTH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DNTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DNTH filings page.
Dianthus Therapeutics, a clinical-stage biotech focused on severe autoimmune diseases, reported a net loss of $50.2M for the quarter and $91.0M for the six months ended June 30, 2026, driven mainly by rising R&D spending on its claseprubart program and discovery work.
R&D expenses reached $48.7M in the quarter and $83.2M year-to-date, while G&A totaled $13.6M and $26.0M, respectively. License revenue from its Tenacia partnership contributed $0.8M in the quarter. A March 2026 equity offering raised $719.0M, alongside ATM share sales of $58.7M, lifting liquidity, with cash and cash equivalents of $110.5M and marketable securities of $1.08B within total assets of $1.21B at June 30, 2026. Management states that existing cash, cash equivalents and investments are expected to fund obligations for at least twelve months beyond the financial statement issuance date, even as the company continues to invest heavily in claseprubart, new candidate DNTH212 and broader pipeline activities.
Dianthus Therapeutics reports a wider Q1 2026 loss alongside a transformative equity raise that greatly strengthens its balance sheet. The company posted a net loss of $40.8M, versus $29.5M a year earlier, as it increased research and development spending to $34.5M and general and administrative costs to $12.5M.
License revenue was modest at $0.5M, so operations remain largely funded by external capital. In March 2026, Dianthus completed a public offering of common stock and pre-funded warrants with gross proceeds of about $719.0M, and also raised $58.7M through an at-the-market program.
These financings drove cash, cash equivalents and short-term investments to approximately $1.11B, with total assets of $1.25B as of March 31, 2026. Management states existing cash, cash equivalents and investments are expected to fund obligations for at least twelve months beyond the financial statement issuance date.
Dianthus Therapeutics (DNTH) reported Q3 2025 results. Revenue was $396 thousand from licensing. Research and development expense rose to $32.5 million and general and administrative expense was $8.2 million, driving a net loss of $36.8 million, or $0.97 per share.
The balance sheet strengthened following a September underwritten offering. Cash and cash equivalents were $55.984 million, with short‑term investments of $346.629 million and long‑term investments of $152.874 million. Total assets reached $577.4 million against total liabilities of $31.0 million, resulting in stockholders’ equity of $546.5 million.
In September, the company sold 7,627,879 shares at $33.00 and issued pre‑funded warrants for 1,112,121 shares at $32.999, for gross proceeds of $288.4 million, to fund development, working capital and general corporate purposes. The ATM program remains available with $160.8 million of capacity. Shares outstanding were 42,876,015 as of November 3, 2025. Management states existing cash, cash equivalents and investments are expected to fund obligations for at least twelve months beyond the financials’ issuance date.